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There is increasing concern about safety in British prisons. Assaults, self-harm and deaths in 
custody are rising (Ministry of Justice, 2019). Substance misuse is a significant cause of 
morbidity and death, and extensive efforts are made to prevent illicit drugs entering prisons 
(Ministry of Justice/HM Prison & Probation Service, 2019).   There are less well-recognised, 
but  nonetheless serious, challenges to the safety of the prison population related to 
prescribing practice for chronic pain in UK primary and secondary care. 
 
The “opioid crisis” in the USA and in the UK 
 
In the USA, a dominant narrative has emerged concerning opioid drugs. To summarise: 
 
From the 1980s, medical attitudes to pain relief radically changed. Analgesic use was 
encouraged by a pharmaceutical industry that claimed that new high-potency synthetic 
opioids were invariably effective, provided sufficiently high doses were prescribed. ‘Big 
Pharma’ erroneously claimed that these drugs carried a low risk of dependency except 
amongst those with a pre-existing addiction problem. The consequence has been that 
millions of Americans have been led into drug addiction and death, in an epidemic that has 
particularly affected small town America, where drug abuse was previously uncommon. (e.g. 
see Quinones, 2016) 
 
Irrespective of the US narrative, it is possible to say with some confidence that the problems 
associated with opioid prescribing in the UK are different.  
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Opioid drug prescriptions/1000 population rose by 34% in England between 1998 and 2016, 
but the aggregated strength of prescribed opioids/annum increased by 127% (when 
measured as oral morphine equivalent doses). Since 2016, prescriptions have stabilised or 
perhaps slightly reduced (Curtis et al., 2019). The long term increase has thus been 
substantial, but does not remotely match the scale of the problem in the USA. In America, 
monitoring and control of prescribing is more difficult than in the UK owing to the US free-
market healthcare system, but, nonetheless, there has been a significant decrease in opioid 
prescriptions from a peak in 2011 (Pezalla et al,. 2017). Unfortunately this has been 
paralleled by an increase in street use. By contrast, although in the UK the increased supply 
of opioids has bled onto the black market, this has not provoked an epidemic of street 
heroin addiction. 
 
Drug misuse, including class A drugs, has not increased in England for over a decade, 
although numbers of deaths related to drug misuse have risen substantially (ONS, 2018). 
The latter may be due in part to the use of very high potency prescription opioids such as 
fentanyl, but in our opinion is just as likely to be due to disinvestment from harm-reduction 
orientated drug dependency services provided by fully trained specialists, which has long 
been recognised as the most effective approach in minimising mortality amongst heroin 
users (e.g. Langendam et al., 2001) 
 
So, the situation in the UK with regard to prescribed opioids and street heroin addiction 
could be seen to be less dramatic than in the USA. Any sense of relief from this, however, 
overlooks the evidence that the UK is in the midst of an epidemic of iatrogenic harm due to 
the widespread use of long-term high-dose opioid drugs in the management of chronic pain. 
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Deprived and marginalised people are especially at risk of chronic pain. Many people in 
prison come from this section of the population which, combined with the unusual nature 
of prison life, creates an ill-recognised additional stream of substance misuse, and the risk of 
professional collusion with it.   
 
Opioids and chronic pain 
It is generally accepted that the international change of heart about pain relief was led from 
the UK. Modern palliative care started in 1967 when Dame Cicely Saunders opened St 
Christopher’s Hospice in Sydenham, South London, which went on to become a beacon site 
for global palliative care. From the outset, early and continuous use of opioids was a key 
component in a multi-faceted strategy to protect patients from dying in pain and distress 
(Baines, 2011).  
 
Directly and indirectly, the palliative care movement has led to major improvements in end-
of-life care. As an unintended consequence, its success has encouraged the development of 
misconceptions about chronic non-cancer pain (CNCP) amongst the public and health 
professions alike, namely: 
 
1. That CNCP can always be eliminated if sufficient doses of strong analgesic drugs are  
administered 
2. That the use of opioids to control pain is rarely associated with problems due to 
tolerance, dependency or addiction 
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3. That exacerbations of CNCP in patients on opioids are necessarily due to worsening 
of underlying, disease-driven, pain (“breakthrough pain”) and that increasing opioid 
dose is the appropriate response 
4. That side effects of opioids are trivial in comparison to therapeutic benefits 
 
Although there are British pain clinicians who would argue that each of these is correct, 
there is a substantial body of opinion, and some reasonably persuasive evidence, 
contradicting each point: 
 
1. Opioids are highly effective short-term analgesics, but there are few or no published 
trials of their long-term or high-dose use (Chou et al., 2015). There are many patients 
who are in pain despite such regimens, clearly demonstrating that CNCP cannot 
always be eliminated through drug treatment.  
2. The development of tolerance to these drugs is invariable, and commences within 
days. The degree of tolerance varies for different effects and between individuals. 
Some develop tolerance to sedation at surprisingly high doses, whilst tolerance to 
respiratory depression is generally less marked. Very few develop significant 
tolerance to inhibition of gut motility, so that all opioid patients are constipated 
3. Fluctuations in chronic pain do not necessarily reflect disease progress. In fact, it is 
the nature of CNCP that it varies hour-by-hour, day-by-day and week-by-week, due 
to physical and emotional variables such as activity and mood. The phenomenon of 
opioid-induced hyperalgesia is not fully understood, but it is probably an intrinsic 
component of tolerance. Its effects are usually unimportant at low doses, but they 
become marked as dose rises. Worsening of pain can be due to opioid-induced 
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hyperalgesia (Mitra, 2008). Increases in dose lead to temporary relief, followed by 
further opioid-induced pain. We have labelled this the ‘pain escalator’, alluding to 
the World Health Organisation’s Pain Ladder (Ballantyne et al., 2016): ladders are 
climbed but escalators carry you upwards. The ‘pain escalator’ is driven by opioid-
induced hyperalgesia: patients come to believed that their underlying pain is 
inexorably rising and can only be controlled by ever-increasing doses of analgesics.  
4. Although many patients find opioid side effects intolerable and quickly discontinue, a 
substantial minority of CNCP patients end up on high doses long term. The absolute 
number in the UK is probably large (we have submitted data for publication 
suggesting at least 100,000). Mortality associated with these drugs is known to 
increase with dose. The full impact of high-dose regimens (commonly defined as 
120mg oral morphine equivalent/day and above) is only clearly seen when patients 
radically reduce, or stop, the drugs over a short timescale. After initial withdrawal is 
over, pain is rarely worse than before and often improves. Sedation stops. There are 
major improvements in cognitive function (especially higher executive functions), 
mood and functional activity. For most, if not all, high dose regimens are not just 
ineffective, they are harmful. 
 
This is no reason for therapeutic nihilism. Many clinicians working with chronic pain believe 
that pain management requires a predominantly psychosocial approach that aims to give 
patients better understanding and control over their pain. There is a role for medication, 
including low-dose opioids, but drugs cannot be expected to resolve chronic pain. For the 
time being, however, opioid medication remains the mainstay of chronic pain management 
in UK health care. This causes problems when patients are sent to prison. 
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Pain medication in the UK prison population 
All illnesses aggregate in the poorest sections of society, owing to powerful effects of social 
determinants of ill-health (Poole et al., 2014), and chronic pain is no exception. Those in the 
population most at risk of imprisonment are particularly likely to be taking prescribed 
opioids. In prison, these drugs are even more problematic than in the wider community. 
They are easily redistributed through the prison population, through sale or intimidation.  
 
The lives of people incarcerated in prison are boring and barren. There are few distractions 
from chronic pain. The ability to “get out of it” temporarily through intoxication is attractive, 
but dangerous. Drugs such as oxycodone are extremely potent. The strongest slow release 
oxycodone tablet contains 120mg (240mg oral morphine equivalent). A very small number 
of tablets can kill someone who is opioid-naive or otherwise vulnerable to respiratory 
depression (many older men in prison have smoking-related lung disease). The problems 
associated with opioids are compounded by the widespread use of gabapentinoid drugs 
(pregabalin and gabapentin). Gabapentinoid use is rising in drug abusing populations, and 
they are implicated in deaths (Evoy et al., 2017) 
 
In prisons, uncritical prescribing of medications reported to have been taken in the 
community is not appropriate, as this undermines the health of individuals and of the prison 
population in general. The introduction of assertive but careful medicines management 
regimens in prison carries the promise of health benefits beyond those that are currently 
enjoyed by the rest of the population, particularly with regard to avoidance of harms with 
no therapeutic value.  
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Medicines management regimens of this sort do exist in some prisons and our group will 
shortly submit an evaluation of one for publication. They rest on prompt and careful 
assessment of the patient’s health status on arrival in prison, which often leads to reduction 
and discontinuation of medications against the patient’s wishes. Patients are generally 
regarded as customers with a host of rights, so this is controversial. However, to prescribe 
knowing that the drugs are causing harm could be considered to be in conflict with the 
medical code, and forced withdrawal of damaging and ineffective medication regimens is 
sometimes necessary in the wider community. Its application in prison does not intrinsically 
involve different standards of care for prison and general populations. On the contrary, it 
could be regarded as a form of equivalence of care. After all, notwithstanding online supply, 
if patients have a right to whatever medication they want, drugs may as well be sold over 
the counter without restriction.  
 
Recently published guidance from the Royal College of General Practitioners Secure 
Environments Group (Royal College of General Practitioners, 2019) carefully addresses these 
points, but this does not prevent controversy. 
 
Resistance 
There is a small group of clinicians and researchers in the UK  working on ways of 
rationalising long-term high-dose opioid regimens, with the objective of improving 
individual pain management, daily functioning and safety. Although they enjoy considerable 
support and encouragement from many colleagues, they have all met with marked 
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institutional and professional opposition as well. Resistance has been particular strong with 
regard to prison medicines management.  
 
In a rational world, UK prisons would offer structured rehabilitation activity for those 
detained, which would include help with chronic health problems. The availability of this at 
present is very poor. Prison patients who have medications reduced or stopped without 
their agreement often become disgruntled when they think that they face increased pain 
and/or boredom, or the loss of a marketable commodity. This has an impact on prison staff, 
who may then become unsupportive of the strategy. Some wider community medical 
colleagues take offence at a perceived accusation of complicity in an iatrogenic problem. In 
our opinion, the problem is not about careless prescribers. The real culprit is an atomised, 
overstretched health system that has not challenged received wisdom about pain relief until 
very recently (Welsh Government, 2019). Prisoners’ families, faced with complaints about 
withdrawal of medications previously sanctioned by doctors, and already understandable 
concerned for their loved ones’ welfare, complain of heartless and inadequate health care. 
Journalists are rarely prepared to construe anything about prisons or those held within 
them as positive, but they are very interested in allegations of neglect involving health 
professionals. Needless to say, those working in this field have to be robust and insist on 
sticking to the rationality and evidence in the face of opposition that can be personally 
threatening. 
 
Conclusion 
Much of the above is based upon experience of working with chronic pain and in prisons for 
many years, together with the limited evidence base. There is a pressing need for research 
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about high-dose opioids in general, and thorough evaluation of the impact of systematic 
and well thought-through approaches to tackle the problem at individual and population 
levels. The prison population is especially vulnerable with regard to abusable drugs, and it is 
important we develop prison-based responses to difficulties that have their origins in the 
mainstream health services. 
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